<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nephrocalcinosis in neonates
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nephrocalcinosis in neonates
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nephrocalcinosis in neonates
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jodi Smith, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            F Bruder Stapleton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph A Garcia-Prats, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H451773996">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nephrocalcinosis is defined as calcium salt deposition in the renal parenchyma including the tubular epithelium and interstitial renal tissue. Nephrocalcinosis in childhood occurs most frequently in neonates, especially preterm infants, because of their renal tubular immaturity and administration of medications and nutritional supplements that promote calcium salt deposition.
        </p>
        <p>
         This topic will review the pathogenesis, etiology, risk factors, and management of neonatal nephrocalcinosis.
        </p>
        <p class="headingAnchor" id="H111578371">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported incidence of neonatal nephrocalcinosis over the last several decades has varied from 7 to 41 percent. Studies in preterm infants, a population particularly susceptible to nephrocalcinosis, have found an incidence of 12 to 26 percent [
         <a href="#rid1">
          1-5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H451774016">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal nephrocalcinosis is caused by calcium salt crystal formation and aggregation within the renal tubules created by an imbalance that promotes
         <strong>
          stone-producing factors
         </strong>
         (increased urinary excretion of calcium, oxalate, and uric acid) over
         <strong>
          stone-inhibiting factors
         </strong>
         (decreased urinary excretion of citrate and magnesium) [
         <a href="#rid1">
          1,6-13
         </a>
         ]. Neonates, and especially premature infants, are at risk for calcium salt crystallization because of renal tubule immaturity and increased likelihood of hypercalciuria (increased promoting factor) and hypocitraturia (loss of inhibiting factor), as discussed below.
        </p>
        <p class="headingAnchor" id="H111582676">
         <span class="h1">
          ETIOLOGY AND RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H111584190">
         <span class="h2">
          Renal tubular immaturity in preterm infants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preterm infants are at increased risk for nephrocalcinosis due to renal tubular immaturity, which increases with decreasing birth weight [
         <a href="#rid14">
          14
         </a>
         ]. Nephrogenesis is not completed until 34 to 36 weeks gestation. As a result, in the developing kidney, there is continuing proliferation of renal epithelium cells within the renal tubule that are thought to be more susceptible to crystal formation and aggregation [
         <a href="#rid15">
          15
         </a>
         ]. Preterm infants have a markedly low glomerular filtration rate (GFR) that results in a low fluid flow rate within the tubular lumen [
         <a href="#rid16">
          16,17
         </a>
         ]. This enhances crystal formation and aggregation, particularly in the setting of tubular fluid supersaturation, which is promoted by hypercalciuria and hypocitraturia (commonly observed findings in preterm infants).
        </p>
        <p>
         Very low birth weight preterm infants (birth weight &lt;1500 g) also have decreased bicarbonate reabsorptive capacity. The increased bicarbonate excretion results in an alkaline urine pH, which directly enhances calcium phosphate precipitation [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H111584309">
         <span class="h2">
          Hypercalciuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypercalciuria promotes crystal and stone formation and is commonly observed in preterm infants [
         <a href="#rid1">
          1,4,6,7,16,19-21
         </a>
         ]. Hypercalciuria can be caused by hypercalcemia, resulting in an increased filtered load of calcium to the kidney, or in patients with normal calcium blood levels due to decreased calcium renal resorption.
        </p>
        <p class="headingAnchor" id="H111584664">
         <span class="h3">
          Hypercalcemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal nephrocalcinosis has been observed as a result of hypercalcemia and hypercalciuria in the following settings [
         <a href="#rid22">
          22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subcutaneous fat necrosis
         </strong>
         – Subcutaneous fat necrosis resulting from inflammation of the subcutaneous fat is a rare complication that can occur following birth trauma, meconium aspiration, or therapeutic cooling. It is associated with severe hypercalcemia, fever, and risk for nephrocalcinosis [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13738.html" rel="external">
          "Subcutaneous fat necrosis of the newborn"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutrition
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcium supplementation
         </strong>
         – Neonatal nephrocalcinosis has been associated with increased calcium and phosphate intake, especially in preterm infants receiving total parenteral nutrition [
         <a href="#rid1">
          1,6,19,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vitamin D therapy
         </strong>
         – Nephrocalcinosis has been reported in infants due to excessive vitamin D supplementation, resulting in hypercalcemia [
         <a href="#rid17">
          17,25
         </a>
         ]. A study of 56 premature infants receiving standard care did not detect a difference in the dose of vitamin D between those who developed nephrocalcinosis and those who did not [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic disorders
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Williams syndrome – Patients with Williams syndrome (caused by hemizygous deletion of 1.5 to 1.8 Mb on chromosome 7q11.23) often have elevated calcium levels and are at risk for developing nephrocalcinosis. Typical clinical neonatal features of this syndrome include "elfin" face, supravalvar aortic stenosis, and hypertension. (See
         <a class="medical medical_review" href="/z/d/html/6127.html" rel="external">
          "Williams syndrome", section on 'Elevated calcium levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Idiopathic infantile hypercalcemia – Idiopathic infantile hypercalcemia is characterized by severe hypercalcemia with failure to thrive, vomiting, dehydration, and nephrocalcinosis. Hypercalcemia resolves during or soon after infancy. It is caused by mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F126065&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1QP%2FbuDO3HskWZg2TU%2FkOED&amp;TOPIC_ID=6125" target="_blank">
          <i>
           CYP24A1
          </i>
         </a>
         gene that encodes the vitamin D enzyme 25-hydroxyvitamin D
         <sub>
          3
         </sub>
         -24-hydroxylase, which leads to accumulation of the active metabolite 1,25-(OH)
         <sub>
          2
         </sub>
         D
         <sub>
          3
         </sub>
         [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congenital lactase deficiency – One small case series described nephrocalcinosis in infants with congenital lactase deficiency due to hypercalcemia and hypercalciuria [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/839.html" rel="external">
          "Etiology of hypercalcemia", section on 'Congenital lactase deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonatal primary hyperparathyroidism
         </strong>
         – Although rare, patients with neonatal primary hyperparathyroidism have hypercalcemia (which is often severe), hypophosphatemia, and a normal or increased plasma alkaline phosphatase level and may present with respiratory distress, failure to thrive, and hypotonia [
         <a href="#rid30">
          30
         </a>
         ]. Rachitic changes often occur, and bone radiographs may reveal subperiosteal resorption. At least some cases of neonatal hyperparathyroidism are familial and are caused by an autosomal recessive disease due to mutations of the gene that encodes the calcium-sensing protein in the parathyroid gland; heterozygotes have less severe disease and present with asymptomatic hypercalcemia and hypercalciuria. (See
         <a class="medical medical_review" href="/z/d/html/838.html" rel="external">
          "Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H759032">
         <span class="h3">
          Normocalcemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two main mechanisms that result in neonatal nephrocalcinosis associated with hypercalciuria and normal blood calcium levels are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications that alter calcium renal absorption, most commonly loop diuretics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic disorders with renal tubular dysfunction that affect calcium renal absorption
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H759123">
         <span class="h4">
          Loop diuretics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nephrocalcinosis is a known complication of loop diuretic therapy in preterm infants due to hypercalciuria [
         <a href="#rid14">
          14,19,21,31
         </a>
         ]. This effect is mediated by inhibition of sodium chloride reabsorption in the thick ascending limb and an associated decline in calcium reabsorption as calcium transport passively follows that of sodium. Hypercalcuria may be prolonged in neonates because there is typically a slower plasma clearance of the diuretic [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">
          "Diuretics and calcium balance"
         </a>
         .)
        </p>
        <p>
         In addition, loop diuretics also may increase urinary phosphate excretion, a probable reflection of decreased proximal phosphate reabsorption induced by the mild carbonic anhydrase inhibitory activity of
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         . Concurrent therapy with
         <a class="drug drug_pediatric" data-topicid="13213" href="/z/d/drug information/13213.html" rel="external">
          acetazolamide
         </a>
         , which inhibits carbonic anhydrase, diminishes proximal tubular transport of calcium, phosphate, and bicarbonate. The net effect appears to be increased urinary calcium and phosphate excretion and an elevation in urine pH. In one report, for example, 7 of 11 infants treated with acetazolamide and furosemide had hypercalciuria; five of these seven infants had nephrocalcinosis [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H759450">
         <span class="h4">
          Other medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other medications identified as risk factors for hypercalcuria and nephrocalcinosis include aminoglycosides [
         <a href="#rid1">
          1,19,35
         </a>
         ] and
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         [
         <a href="#rid19">
          19,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H111582706">
         <span class="h4">
          Genetic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic disorders that result in renal tubular dysfunction have been associated with hypercalciuria and nephrocalcinosis and include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bartter syndrome – Bartter syndrome is due to gene mutations of proteins that are involved in sodium chloride reabsorption in the medullary thick ascending limb of the loop of Henle. These mutations result in impaired sodium reabsorption (similar to that seen with loop diuretic therapy), which is accompanied by a decline in calcium reabsorption leading to hypercalciuria. Neonates with severe autosomal recessive disease present with polyhydramnios and prematurity. If untreated, these infants develop severe metabolic acidosis with poor growth, rickets, and nephrocalcinosis. (See
         <a class="medical medical_review" href="/z/d/html/131435.html" rel="external">
          "Bartter and Gitelman syndromes in children: Clinical manifestations, diagnosis, and management", section on 'Laboratory findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Additional features of the Bartter-like phenotype'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distal (type 1) renal tubular acidosis (RTA) – Genetic causes of distal RTA include mutations of genes that encode the chloride-bicarbonate exchanger (AE1) or subunits of the H-ATPase pump. Infants with autosomal recessive forms of distal RTA typically have more severe diseases and, if untreated, develop severe metabolic acidosis, poor growth, rickets, and nephrocalcinosis  (
         <a class="graphic graphic_table graphicRef59008" href="/z/d/graphic/59008.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">
          "Etiology and clinical manifestations of renal tubular acidosis in infants and children", section on 'Distal (type 1) renal tubular acidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Familial primary hypomagnesemia is a rare autosomal recessive condition with renal calcium and magnesium wasting. The clinical features include nephrocalcinosis, progressive kidney failure, and eye abnormalities. The etiology is due to mutations in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603959&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr2kNheaVBiA5VmRIqvgtAC&amp;TOPIC_ID=6125" target="_blank">
          <i>
           CLDN16
          </i>
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610036&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5LST98evZztXzdHInsvIMl&amp;TOPIC_ID=6125" target="_blank">
          <i>
           CLDN19
          </i>
         </a>
         . Ocular abnormalities occur only with
         <em>
          CDLN19
         </em>
         mutations. Clinical symptoms present from 1 to 14 years [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/829.html" rel="external">
          "Hypomagnesemia: Causes of hypomagnesemia", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other genetic diseases associated with hypercalcemia and subsequent later development of nephrocalcinosis beyond the neonatal period include Dent disease and Lowe oculocerebrorenal syndrome. (See
         <a class="medical medical_review" href="/z/d/html/7363.html" rel="external">
          "Dent disease (X-linked recessive nephrolithiasis)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7363.html" rel="external">
          "Dent disease (X-linked recessive nephrolithiasis)", section on 'Lowe syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/838.html" rel="external">
          "Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7209.html" rel="external">
          "Nephrocalcinosis", section on 'Inherited tubulopathies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypophosphatasia is an autosomal recessive condition, which occurs due to mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F171760&amp;token=tEpDslnpc0F0kICl%2Fz7sFRpMsbswgmBJuV5MFhYv5gAnL6bViDzu5hM%2FxZdXOnS1&amp;TOPIC_ID=6125" target="_blank">
          <i>
           ALPL
          </i>
         </a>
         gene. Affected neonates present with defective bone mineralization leading to rickets, osteomalacia, fractures, and severe periodontal disease, as well as hypercalcemia, hypercalciuria, and nephrocalcinosis [
         <a href="#rid38">
          38
         </a>
         ] (See
         <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">
          "Epidemiology and etiology of osteomalacia", section on 'Hypophosphatasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H759747">
         <span class="h2">
          Hypocitraturia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Citrate is a potent inhibitor of calcium stone formation, primarily by combining with calcium to form a nondissociable but highly soluble complex (see
         <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">
          "Kidney stones in adults: Epidemiology and risk factors"
         </a>
         ). In very low birth weight infants (birth weight &lt;1500 g), low urinary citrate excretion is a common finding in patients with nephrocalcinosis [
         <a href="#rid8">
          8
         </a>
         ]. Urinary citrate excretion decreases in patients with persistent metabolic acidosis, which often occurs in ill preterm infants.
        </p>
        <p class="headingAnchor" id="H3642903630">
         <span class="h2">
          Increased urine oxalate excretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary hyperoxaluria type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism caused by a deficiency of the liver-specific enzyme alanine glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary excretion of oxalate, which may cause nephrocalcinosis in the neonatal period [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">
          "Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H451774301">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nephrocalcinosis is an asymptomatic condition. It is discovered as an incidental finding when abdominal or chest imaging is performed for another reason or when renal ultrasound screening is performed for at-risk infants. This includes the following clinical settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic loop diuretic therapy, which is typically reserved for ventilator-dependent infants with severe bronchopulmonary dysplasia who are not responsive to modest fluid restriction and/or thiazide therapy. (See
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Diuretics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent hypercalcemia resulting in hypercalcuria such as in patients with hypervitaminosis D. (See
         <a class="local">
          'Hypercalcemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with hypercalcuria due to genetic diseases that result in hypercalcemia (eg, Williams-Beuren syndrome) or renal tubular dysfunction (eg, Bartter syndrome). (See
         <a class="local">
          'Genetic disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H760495">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinalysis for patients with neonatal nephrocalcinosis is not useful, as the findings are usually benign. On occasion, urinalysis may reveal nonspecific findings of hematuria or sterile pyuria.
        </p>
        <p class="headingAnchor" id="H760376">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of nephrocalcinosis is made by imaging. In the neonate, renal ultrasound is the modality usually used to make the diagnosis of nephrocalcinosis  (
         <a class="graphic graphic_diagnosticimage graphicRef106015" href="/z/d/graphic/106015.html" rel="external">
          image 1
         </a>
         ), although nephrocalcinosis can also be detected by abdominal or whole-body radiography or computed tomography (CT) [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H760543">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnostic evaluation is initiated to determine the underlying cause.
        </p>
        <p class="headingAnchor" id="H432869320">
         <span class="h2">
          Initial evaluation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical history
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of consanguinity or positive family history for renal tubular dysfunction or stone disease may be indicative of an underlying genetic disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Review of medications or nutritional intake that increase urinary calcium excretion (eg, loop diuretics,
         <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">
          dexamethasone
         </a>
         , and supplemental calcium and vitamin D).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medical conditions associated with nephrocalcinosis (eg, prematurity, subcutaneous fat necrosis, or history of polyhydramnios [Bartter syndrome]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         for features suggestive of an underlying genetic disorder such as Williams-Beuren syndrome (elfin facies, supravalvular aortic stenosis, hypertension). (See
         <a class="medical medical_review" href="/z/d/html/6127.html" rel="external">
          "Williams syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serum electrolytes
         </strong>
         – Hypokalemia and metabolic acidosis are features observed with distal renal tubular acidosis (RTA); hypokalemia and metabolic alkalosis are features of Bartter syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcium
         </strong>
         – Hypercalcemia leads to hypercalciuria. (See
         <a class="local">
          'Hypercalcemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Urine calcium-to-creatinine ratio
         </strong>
         – Infants have a higher urinary calcium excretion rate and urine calcium/creatinine ratio. Hypercalciuria for infants less than six months of age is defined as a ratio &gt;0.8 mg/mg (2.25 mmol/mmol) [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="local">
          'Hypercalciuria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Urinalysis
         </strong>
         – Urine pH &gt;5.3 with a low serum bicarbonate are features of distal RTA. A low specific gravity may be indicative of impaired ability for urinary concentration, which is a feature in Bartter syndrome.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2826463069">
         <span class="h2">
          Further evaluation if necessary
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a diagnosis is still not established after this initial evaluation, further laboratory testing may be performed and includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urine anion gap
         </strong>
         – A positive urine anion gap in the presence of normal anion gap metabolic acidosis is suggestive of distal RTA. (See
         <a class="medical medical_review" href="/z/d/html/6100.html" rel="external">
          "Approach to the child with metabolic acidosis", section on 'Normal anion gap'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinary oxalate level
         </strong>
         – Elevated urinary oxalate is suggestive of primary hyperoxaluria type 1. (See
         <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">
          "Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum alkaline phosphatase level
         </strong>
         – Patients with hypophosphatasia have low alkaline phosphatase levels. (See
         <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">
          "Epidemiology and etiology of osteomalacia", section on 'Hypophosphatasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic testing
         </strong>
         – This is becoming more useful in the diagnosis of children with nephrocalcinosis without a clinical diagnosis. Whole-exon sequencing of children with nephrocalcinosis, with or without nephrolithiasis, identified gene mutations that provided information supplementing clinical evaluation [
         <a href="#rid43">
          43-45
         </a>
         ]. These studies found that monogenetic mutations occurred in 5 to 30 percent of study cohorts. Genetic mutations most often occurred in recessive genes. Although mutations occurred in children at all ages, they were particularly common in children in the first three years of age. Mutations occurred equally in males and females. (See
         <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">
          "Etiology and clinical manifestations of renal tubular acidosis in infants and children", section on 'Distal (type 1) renal tubular acidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin D and parathyroid hormone
         </strong>
         – In patients with hypercalcemia, serum vitamin D or parathyroid hormone levels may help to diagnosis hypervitaminosis D or hyperparathyroidism.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H451774307">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial management of neonatal nephrocalcinosis is directed to treating the underlying cause, if possible:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with nephrocalcinosis secondary to loop diuretic therapy (eg,
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         ), hypercalciuria is eliminated by stopping loop diuretic therapy. Administration of a thiazide diuretic can used as an alternative if diuretic therapy is still needed [
         <a href="#rid40">
          40,46
         </a>
         ]. This change may not be tolerated in ventilator-dependent infants with severe bronchopulmonary dysplasia. In these patients, a short course of furosemide may be used in combination with chronic thiazide diuretic therapy. (See
         <a class="medical medical_review" href="/z/d/html/4977.html" rel="external">
          "Bronchopulmonary dysplasia (BPD): Management and outcome", section on 'Diuretics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Discontinuation of loop diuretic therapy typically results in resolution of nephrocalcinosis over time [
         <a href="#rid2">
          2,7,40,47-50
         </a>
         ]. (See
         <a class="local">
          'Outcome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with high calcium and phosphorus dietary intake, modification of dietary intake (especially total parenteral nutrition) by lowering calcium and phosphorus intake should be undertaken if possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapy for the following genetic disorders is directed toward addressing metabolic abnormalities that contribute to renal tubular calcium salt deposition.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Distal renal tubular acidosis (RTA)
         </strong>
         – Correction of metabolic acidosis with alkali therapy (eg,
         <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">
          sodium bicarbonate
         </a>
         or sodium citrate) minimizes calcium deposition. (See
         <a class="medical medical_review" href="/z/d/html/2329.html" rel="external">
          "Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) renal tubular acidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bartter syndrome
         </strong>
         – Treatment is supportive and is focused on minimizing metabolic abnormalities caused by the underlying genetic defect. Primary initial intervention consists of administration of nonsteroidal antiinflammatory drugs. (See
         <a class="medical medical_review" href="/z/d/html/131435.html" rel="external">
          "Bartter and Gitelman syndromes in children: Clinical manifestations, diagnosis, and management", section on 'Postnatal therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Williams syndrome
         </strong>
         – Therapy is directed toward correcting hypercalcemia. Supportive measures include fluid administration,
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         treatment, and calcium restriction. Case reports have shown that bisphosphonates may be helpful in severe cases; however, it remains unclear whether these agents are both efficacious and safe. (See
         <a class="medical medical_review" href="/z/d/html/6127.html" rel="external">
          "Williams syndrome", section on 'Elevated calcium levels'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Idiopathic infantile hypercalcemia
         </strong>
         – Therapy includes phosphate supplementation and restriction of calcium and vitamin D supplementation [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional supportive measures to reduce urinary calcium concentration in patients with hypercalciuria may be needed and include increasing fluid intake and administration of thiazide diuretics.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other possible modalities, which have not been well evaluated, include the administration of sodium citrate,
         <a class="drug drug_pediatric" data-topicid="16457" href="/z/d/drug information/16457.html" rel="external">
          potassium citrate-citric acid
         </a>
         , oral phosphate, and
         <a class="drug drug_pediatric" data-topicid="12673" href="/z/d/drug information/12673.html" rel="external">
          pamidronate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of citrate therapy has been proposed as a means of preventing nephrocalcinosis. However, in a randomized controlled trial of 74 preterm infants with a gestational age less than 32 weeks, there was no difference in the incidence of nephrocalcinosis between infants who received sodium citrate and control infants (34 versus 44 percent) [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">
          "Diuretics and calcium balance"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7373.html" rel="external">
          "Kidney stones in adults: Prevention of recurrent kidney stones"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In small case series, bisphosphonates (
         <a class="drug drug_pediatric" data-topicid="12673" href="/z/d/drug information/12673.html" rel="external">
          pamidronate
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="121845" href="/z/d/drug information/121845.html" rel="external">
          zoledronic acid
         </a>
         ) have been reported to be successful in the treatment of severe hypercalcemia in neonatal subcutaneous fat necrosis [
         <a href="#rid51">
          51-53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13738.html" rel="external">
          "Subcutaneous fat necrosis of the newborn", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H451774389">
         <span class="h2">
          Follow-up after neonatal intensive care unit discharge
         </span>
         <span class="headingEndMark">
          —
         </span>
         Follow-up after neonatal intensive care unit discharge involves ongoing and comprehensive reassessment of the patient's renal status. Timing of follow-up is based on the severity of the nephrocalcinosis, renal function, and therapy. Any neonate who is receiving medical management should be seen within a month of discharge. Subsequent visits are scheduled based on individual clinical factors. Follow-up includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serial renal ultrasonography, with annual imaging for the first few years. Subsequent evaluations are based on the progress or resolution of nephrocalcinosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney function studies should be followed based on clinical evaluation and changes on ultrasonography. Urine calcium-to-creatinine ratio to detect and monitor hypercalciuria may be indicated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H761573">
         <span class="h1">
          OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         The outcome of neonatal nephrocalcinosis is determined by the underlying cause. In most cases of nephrocalcinosis that occur in preterm infants without an underlying genetic defect, there is spontaneous resolution in the first several years of life [
         <a href="#rid2">
          2,7,49
         </a>
         ]. In particular, nephrocalcinosis induced by loop diuretics resolves over time in the majority of infants after cessation of the diuretic [
         <a href="#rid2">
          2,7,40,47-50
         </a>
         ].
        </p>
        <p>
         It remains uncertain whether nephrocalcinosis affects renal function and growth as data are limited and results are conflicting.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several studies have shown no evidence of renal impairment associated with nephrocalcinosis [
         <a href="#rid7">
          7,9,50
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one case series, 14 children who were preterm infants with nephrocalcinosis had similar renal function as normal matched controls (sex, gestational age, and birth weight) at five to seven years of age [
         <a href="#rid7">
          7
         </a>
         ]. Of note, three patients had evidence of persistent nephrocalcinosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a second case series, there was no difference in renal size urinary calcium excretion or renal concentration ability between preterm survivors with neonatal nephrocalcinosis compared with matched controls at four to five years of age [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, other studies have reported an association between neonatal nephrocalcinosis and long-term renal dysfunction:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one study, creatinine clearance at one to two years of age was lower in 10 preterm survivors with renal calcifications associated with
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         therapy compared with two control groups: group 1 with no furosemide therapy or renal calcification, and group 2 who were treated with furosemide but had no renal calcifications [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a relatively large case series, 6 of 40 preterm survivors with neonatal nephrocalcinosis had a glomerular filtration rate (GFR) below 85 mL/min per 1.73 m
         <sup>
          2
         </sup>
         compared with 2 of 32 controls without nephrocalcinosis at a mean age of 7.5 years [
         <a href="#rid49">
          49
         </a>
         ]. Children with neonatal nephrocalcinosis compared with controls also had lower tubular phosphate reabsorption and plasma bicarbonate levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed results were reported in a large case series of 63 children with neonatal nephrocalcinosis and matched controls at two years of life [
         <a href="#rid54">
          54
         </a>
         ]. In this cohort, there was no difference between the two groups regarding serum creatinine levels and estimated GFR; however, children with neonatal nephrocalcinosis had shorter kidney length (detected by renal ultrasound) for both kidneys at one year of age and only for the right kidney at two years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 60 children who were extremely preterm, nephrocalcinosis was identified as a potential contributing factor to poor kidney growth and volume [
         <a href="#rid55">
          55
         </a>
         ]; GFR measured by cystatin C was lower in children with nephrocalcinosis but remained in the normal range. Ambulatory blood pressure at a mean age of 7.7 years was normal in children with nephrocalcinosis.
        </p>
        <p>
        </p>
        <p>
         We continue to recommend follow-up to monitor both kidney growth and function based on ultrasonographic findings and general clinical health. (See
         <a class="local">
          'Follow-up after neonatal intensive care unit discharge'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H451774705">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and incidence
         </strong>
         – Nephrocalcinosis is defined as deposits of calcium salts in the renal parenchyma. Nephrocalcinosis occurs more frequently in neonates, especially preterm infants because of their renal tubular immaturity and administration of medications and nutritional supplements that promote calcium salt deposition. The reported incidence of nephrocalcinosis in preterm infants ranges from 7 to 41 percent. (See
         <a class="local">
          'Incidence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology and risk factors
         </strong>
         – Risk factors for neonatal nephrocalcinosis include prematurity, administration of loop diuretics, increased dietary calcium, and vitamin D supplementation. Genetic disorders associated with neonatal nephrocalcinosis include those with hypercalcemia (Williams-Beuren syndrome and idiopathic infantile hypercalcemia) and those with hypercalcuria in the setting of normal blood levels of calcium (distal renal tubular acidosis [RTA] and Bartter syndrome). (See
         <a class="local">
          'Etiology and risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Neonates with nephrocalcinosis are asymptomatic. Nephrocalcinosis presents as either an incidental finding when renal imaging is performed for another reason or when renal ultrasound screening is performed for at-risk infants. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis is typically made by renal ultrasound  (
         <a class="graphic graphic_diagnosticimage graphicRef106015" href="/z/d/graphic/106015.html" rel="external">
          image 1
         </a>
         ), although nephrocalcinosis can be detected by whole-body or abdominal radiography or CT. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – An initial diagnostic evaluation is performed for all neonates with nephrocalcinosis to determine the underlying cause (if possible). It includes a focused medical history and laboratory evaluation that includes urine and blood tests to detect hypercalcemia, hypercalciuria, impaired urinary concentrating ability or distal renal acidification, and alterations in acid/base status (eg, metabolic acidosis and alkalosis). (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The initial management of neonatal nephrocalcinosis is directed toward treating the underlying cause. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For infants with nephrocalcinosis due to medications (eg, loop diuretics) or nutritional supplementation (eg, calcium or vitamin D), elimination of the causative agent is usually sufficient to stop further progression of calcium salt deposition and begin nephrocalcinosis resolution.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For furosemide-associated nephrocalcinosis in preterm infants, we recommend discontinuation of
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         and, if diuretic therapy is deemed necessary, replacement with a thiazide diuretic (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For infants with genetic disorders, therapy is directed toward addressing the metabolic abnormalities that contribute to the development of nephrocalcinosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up and outcome
         </strong>
         – Although nephrocalcinosis resolves in the majority of cases, it remains unclear whether nephrocalcinosis results in significant chronic kidney injury. As a result, continued follow-up of affected patients is required to ascertain the long-term renal effect of neonatal nephrocalcinosis. (See
         <a class="local">
          'Outcome'
         </a>
         above and
         <a class="local">
          'Follow-up after neonatal intensive care unit discharge'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schell-Feith EA, Kist-van Holthe JE, Conneman N, et al. Etiology of nephrocalcinosis in preterm neonates: association of nutritional intake and urinary parameters. Kidney Int 2000; 58:2102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe B, Duran I, Martin A, et al. Nephrocalcinosis in preterm infants: a single center experience. Pediatr Nephrol 2002; 17:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narendra A, White MP, Rolton HA, et al. Nephrocalcinosis in preterm babies. Arch Dis Child Fetal Neonatal Ed 2001; 85:F207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hein G, Richter D, Manz F, et al. Development of nephrocalcinosis in very low birth weight infants. Pediatr Nephrol 2004; 19:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fayard J, Pradat P, Lorthois S, et al. Nephrocalcinosis in very low birth weight infants: incidence, associated factors, and natural course. Pediatr Nephrol 2022; 37:3093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacinto JS, Modanlou HD, Crade M, et al. Renal calcification incidence in very low birth weight infants. Pediatrics 1988; 81:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter E, McKie A, Beattie TJ, et al. Neonatal nephrocalcinosis: long term follow up. Arch Dis Child Fetal Neonatal Ed 2006; 91:F333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sikora P, Roth B, Kribs A, et al. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney Int 2003; 63:2194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saarela T, Lanning P, Koivisto M. Prematurity-associated nephrocalcinosis and kidney function in early childhood. Pediatr Nephrol 1999; 13:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonntag J, Schaub J. Oxalate excretion during the first 7 weeks in very-low-birth-weight infants. Biol Neonate 1997; 71:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JL, Mendoza SA. Decreased urinary citrate in premature infants with lung disease. Child Nephrol Urol 1990; 10:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schell-Feith EA, Moerdijk A, van Zwieten PH, et al. Does citrate prevent nephrocalcinosis in preterm neonates? Pediatr Nephrol 2006; 21:1830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giapros VI, Papaloukas AL, Challa AS, et al. Urinary lithogenic and inhibitory factors in preterm neonates receiving either total parenteral nutrition or milk formula. Eur J Pediatr 2003; 162:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gimpel C, Krause A, Franck P, et al. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int 2010; 52:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asselman M, Verhulst A, De Broe ME, Verkoelen CF. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003; 14:3155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schell-Feith EA, Kist-van Holthe JE, van der Heijden AJ. Nephrocalcinosis in preterm neonates. Pediatr Nephrol 2010; 25:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habbig S, Beck BB, Hoppe B. Nephrocalcinosis and urolithiasis in children. Kidney Int 2011; 80:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams ND, Rowe JC. Nephrocalcinosis. Clin Perinatol 1992; 19:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed GB, Ibrahiem MA, Abdel Hameed WM. Nephrocalcinosis in pre-term neonates: a study of incidence and risk factors. Saudi J Kidney Dis Transpl 2014; 25:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasseri F, Azhir A, Rahmanian S, et al. Nephrocalcinosis in very low birth weight infants. Saudi J Kidney Dis Transpl 2010; 21:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pope JC 4th, Trusler LA, Klein AM, et al. The natural history of nephrocalcinosis in premature infants treated with loop diuretics. J Urol 1996; 156:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koltin D, Rachmiel M, Wong BY, et al. Mild infantile hypercalcemia: diagnostic tests and outcomes. J Pediatr 2011; 159:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shumer DE, Thaker V, Taylor GA, Wassner AJ. Severe hypercalcaemia due to subcutaneous fat necrosis: presentation, management and complications. Arch Dis Child Fetal Neonatal Ed 2014; 99:F419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe B, Hesse A, Neuhaus T, et al. Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition. Arch Dis Child 1993; 69:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ketha H, Wadams H, Lteif A, Singh RJ. Iatrogenic vitamin D toxicity in an infant--a case report and review of literature. J Steroid Biochem Mol Biol 2015; 148:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malone Jenkins S, Chan G, Weaver-Lewis K, et al. Vitamin D, bone density, and nephrocalcinosis in preterm infants: a prospective study. Pediatr Nephrol 2022; 37:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlingmann KP, Ruminska J, Kaufmann M, et al. Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia. J Am Soc Nephrol 2016; 27:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueres ML, Linglart A, Bienaime F, et al. Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am J Kidney Dis 2015; 65:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saarela T, Similä S, Koivisto M. Hypercalcemia and nephrocalcinosis in patients with congenital lactase deficiency. J Pediatr 1995; 127:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orwoll E, Silbert J, McClung M. Asymptomatic neonatal familial hypercalcemia. Pediatrics 1982; 69:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang HY, Hsu CH, Tsai JD, et al. Renal calcification in very low birth weight infants. Pediatr Neonatol 2011; 52:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aranda JV, Lambert C, Perez J, et al. Metabolism and renal elimination of furosemide in the newborn infant. J Pediatr 1982; 101:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson RG, Simmons MA, Rumack BH, et al. Pharmacology of furosemide in the premature newborn infant. J Pediatr 1980; 97:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stafstrom CE, Gilmore HE, Kurtin PS. Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus. Pediatr Neurol 1992; 8:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andronikou S, Giapros VI, Cholevas VI, Papadopoulou ZL. Effect of aminoglycoside therapy on renal function in full-term infants. Pediatr Nephrol 1996; 10:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cranefield DJ, Odd DE, Harding JE, Teele RL. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone. Pediatr Radiol 2004; 34:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godron A, Harambat J, Boccio V, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin J Am Soc Nephrol 2012; 7:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev 2013; 10 Suppl 2:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leumann EP, Niederwieser A, Fanconi A. New aspects of infantile oxalosis. Pediatr Nephrol 1987; 1:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezzedeen F, Adelman RD, Ahlfors CE. Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr 1988; 113:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saarela T, Vaarala A, Lanning P, Koivisto M. Incidence, ultrasonic patterns and resolution of nephrocalcinosis in very low birthweight infants. Acta Paediatr 1999; 88:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bert S, Gouyon JB, Semama DS. Calcium, sodium and potassium urinary excretion during the first five days of life in very preterm infants. Biol Neonate 2004; 85:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun DA, Lawson JA, Gee HY, et al. Prevalence of Monogenic Causes in Pediatric Patients with Nephrolithiasis or Nephrocalcinosis. Clin J Am Soc Nephrol 2016; 11:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daga A, Majmundar AJ, Braun DA, et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int 2018; 93:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halbritter J, Baum M, Hynes AM, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 2015; 26:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itami N, Kawaguti M, Akutsu Y, et al. Renal calcifications in preterm infants. J Pediatr 1989; 114:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downing GJ, Egelhoff JC, Daily DK, Alon U. Furosemide-related renal calcifications in the premature infant. A longitudinal ultrasonographic study. Pediatr Radiol 1991; 21:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downing GJ, Egelhoff JC, Daily DK, et al. Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years. J Pediatr 1992; 120:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kist-van Holthe JE, van Zwieten PH, Schell-Feith EA, et al. Is nephrocalcinosis in preterm neonates harmful for long-term blood pressure and renal function? Pediatrics 2007; 119:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones CA, King S, Shaw NJ, Judd BA. Renal calcification in preterm infants: follow up at 4-5 years. Arch Dis Child Fetal Neonatal Ed 1997; 76:F185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesover AD, Harrington J, Mahmud FH. Pamidronate as first-line treatment of hypercalcemia in neonatal subcutaneous fat necrosis: A case series. Paediatr Child Health 2021; 26:e52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alos N, Eugène D, Fillion M, et al. Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. Horm Res 2006; 65:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samedi VM, Yusuf K, Yee W, et al. Neonatal hypercalcemia secondary to subcutaneous fat necrosis successfully treated with pamidronate: a case series and literature review. AJP Rep 2014; 4:e93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giapros V, Tsoni C, Challa A, et al. Renal function and kidney length in preterm infants with nephrocalcinosis: a longitudinal study. Pediatr Nephrol 2011; 26:1873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rakow A, Laestadius Å, Liliemark U, et al. Kidney volume, kidney function, and ambulatory blood pressure in children born extremely preterm with and without nephrocalcinosis. Pediatr Nephrol 2019; 34:1765.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6125 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044231" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Etiology of nephrocalcinosis in preterm neonates: association of nutritional intake and urinary parameters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956879" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Nephrocalcinosis in preterm infants: a single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11668166" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Nephrocalcinosis in preterm babies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15054644" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Development of nephrocalcinosis in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35348900" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Nephrocalcinosis in very low birth weight infants: incidence, associated factors, and natural course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3275932" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Renal calcification incidence in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16705005" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Neonatal nephrocalcinosis: long term follow up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753307" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10603142" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prematurity-associated nephrocalcinosis and kidney function in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9167848" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Oxalate excretion during the first 7 weeks in very-low-birth-weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2253255" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Decreased urinary citrate in premature infants with lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17039333" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Does citrate prevent nephrocalcinosis in preterm neonates?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12750999" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Urinary lithogenic and inhibitory factors in preterm neonates receiving either total parenteral nutrition or milk formula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19460127" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14638914" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18797936" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nephrocalcinosis in preterm neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21956187" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nephrocalcinosis and urolithiasis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1576767" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24625999" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nephrocalcinosis in pre-term neonates: a study of incidence and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20228514" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Nephrocalcinosis in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8683766" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The natural history of nephrocalcinosis in premature infants treated with loop diuretics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21414629" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Mild infantile hypercalcemia: diagnostic tests and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24907163" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Severe hypercalcaemia due to subcutaneous fat necrosis: presentation, management and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8215570" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25636720" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Iatrogenic vitamin D toxicity in an infant--a case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34595571" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Vitamin D, bone density, and nephrocalcinosis in preterm infants: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26047794" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25446019" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8523189" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hypercalcemia and nephrocalcinosis in patients with congenital lactase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7054744" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Asymptomatic neonatal familial hypercalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21703556" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Renal calcification in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7131159" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Metabolism and renal elimination of furosemide in the newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7381633" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pharmacology of furosemide in the premature newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1622512" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8971904" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of aminoglycoside therapy on renal function in full-term infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14624322" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22422540" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23858621" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hypophosphatasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3153328" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : New aspects of infantile oxalosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3045282" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Renal calcification in preterm infants: pathophysiology and long-term sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10419252" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Incidence, ultrasonic patterns and resolution of nephrocalcinosis in very low birthweight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14631165" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Calcium, sodium and potassium urinary excretion during the first five days of life in very preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26787776" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prevalence of Monogenic Causes in Pediatric Patients with Nephrolithiasis or Nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28893421" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25296721" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2723903" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Renal calcifications in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1815176" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Furosemide-related renal calcifications in the premature infant. A longitudinal ultrasonographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1552401" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17332199" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Is nephrocalcinosis in preterm neonates harmful for long-term blood pressure and renal function?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9175949" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Renal calcification in preterm infants: follow up at 4-5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33542779" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pamidronate as first-line treatment of hypercalcemia in neonatal subcutaneous fat necrosis: A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16612105" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25452891" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Neonatal hypercalcemia secondary to subcutaneous fat necrosis successfully treated with pamidronate: a case series and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21533868" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Renal function and kidney length in preterm infants with nephrocalcinosis: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31338588" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Kidney volume, kidney function, and ambulatory blood pressure in children born extremely preterm with and without nephrocalcinosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
